StockNews.com Downgrades OPKO Health (NASDAQ:OPK) to Sell

OPKO Health (NASDAQ:OPK) was downgraded by analysts at StockNews.com from a “hold” rating to a “sell” rating in a research note issued on Thursday.

OPK has been the topic of several other reports. HC Wainwright reiterated a “buy” rating and issued a $3.00 price objective on shares of OPKO Health in a report on Thursday, September 26th. Piper Sandler reiterated an “overweight” rating and set a $3.00 price target on shares of OPKO Health in a research report on Tuesday, September 17th. Finally, Barrington Research restated an “outperform” rating and issued a $2.25 price objective on shares of OPKO Health in a report on Friday, November 8th.

OPKO Health Stock Performance

NASDAQ:OPK opened at $1.48 on Thursday. The company has a fifty day moving average of $1.55 and a two-hundred day moving average of $1.48. OPKO Health has a fifty-two week low of $0.85 and a fifty-two week high of $1.76. The stock has a market capitalization of $1.01 billion, a PE ratio of -7.79 and a beta of 1.62. The company has a debt-to-equity ratio of 0.30, a quick ratio of 2.69 and a current ratio of 2.97.

Insider Transactions at OPKO Health

In other news, CEO Phillip Md Et Al Frost bought 125,000 shares of the firm’s stock in a transaction that occurred on Friday, December 13th. The shares were purchased at an average price of $1.59 per share, with a total value of $198,750.00. Following the purchase, the chief executive officer now owns 212,536,477 shares in the company, valued at approximately $337,932,998.43. The trade was a 0.06 % increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. In the last ninety days, insiders acquired 1,304,255 shares of company stock worth $2,024,605. 47.26% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On OPKO Health

Several institutional investors have recently bought and sold shares of OPK. CIBC Asset Management Inc grew its stake in shares of OPKO Health by 79.1% in the second quarter. CIBC Asset Management Inc now owns 20,322 shares of the biotechnology company’s stock worth $25,000 after acquiring an additional 8,978 shares in the last quarter. FMR LLC boosted its holdings in OPKO Health by 103.6% in the third quarter. FMR LLC now owns 21,795 shares of the biotechnology company’s stock valued at $32,000 after purchasing an additional 11,089 shares during the period. Algert Global LLC acquired a new position in OPKO Health during the 2nd quarter worth $44,000. Orion Portfolio Solutions LLC acquired a new position in OPKO Health during the 3rd quarter worth $45,000. Finally, Private Advisor Group LLC increased its holdings in OPKO Health by 242.7% during the 3rd quarter. Private Advisor Group LLC now owns 35,301 shares of the biotechnology company’s stock worth $53,000 after purchasing an additional 25,000 shares during the period. 64.63% of the stock is owned by institutional investors and hedge funds.

OPKO Health Company Profile

OPKO Health, Inc, a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers, and governmental units; and 4Kscore prostate cancer test.